We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+16.07%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$758M
AUM Growth
+$50.6M
Cap. Flow
+$36.9M
Cap. Flow %
4.87%
Top 10 Hldgs %
65.47%
Holding
63
New
21
Increased
16
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
RZLT icon
Rezolute
RZLT
+$42.2M
2
CBIO
Crescent Biopharma
CBIO
+$15M
3
ACOG
Alpha Cognition
ACOG
+$12.4M
4
SLGL icon
Sol-Gel Technologies
SLGL
+$9.61M
5
URGN icon
UroGen Pharma
URGN
+$5.82M

Top Sells

Rank Stock Value
1
IMNM icon
Immunome
IMNM
+$37.3M
2
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$14M
3
CDXS icon
Codexis
CDXS
+$12.2M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$11.3M
5
LRMR icon
Larimar Therapeutics
LRMR
+$10.6M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HROW icon
1
Harrow
HROW
$1.4B
$191M 25.25%
3,905,000
– –
LQDA icon
2
Liquidia Corp
LQDA
$6.06B
$85M 11.21%
2,435,000
-180,000
-7% -$5.12M
ETON icon
3
Eton Pharmaceutcials
ETON
$1.71B
$48.4M 6.38%
2,860,000
– –
RYTM icon
4
Rhythm Pharmaceuticals
RYTM
$7.38B
$35.3M 4.66%
330,000
-131,700
-29% -$14M
APGE icon
5
Apogee Therapeutics
APGE
$10.2B
$29.3M 3.87%
388,257
+25,000
+7% +$1.57M
SNWV
6
SANUWAVE Health Inc
SNWV
$40.2M
$29.3M 3.86%
981,267
+1,267
+0.1% +$40.6K
STOK icon
7
Stoke Therapeutics
STOK
$2.04B
$22.1M 2.91%
695,000
+12,983
+2% +$390K
OCUL icon
8
Ocular Therapeutix
OCUL
$2.28B
$19.4M 2.55%
1,595,000
– –
SLGL icon
9
Sol-Gel Technologies
SLGL
$225M
$19.1M 2.52%
453,739
+248,904
+122% +$9.61M
CGON icon
10
CG Oncology
CGON
$6.59B
$17M 2.25%
410,000
– –
TGTX icon
11
TG Therapeutics
TGTX
$8.26B
$15.9M 2.1%
535,000
– –
IRON icon
12
Disc Medicine
IRON
$3.07B
$15.9M 2.1%
200,000
+6,227
+3% +$526K
RZLT icon
13
Rezolute
RZLT
$445M
$14.8M 1.96%
6,287,156
+5,383,714
+596% +$42.2M
CBIO
14
Crescent Biopharma
CBIO
$659M
$14M 1.84%
+1,178,300
New +$15M
ALKS icon
15
Alkermes
ALKS
$7.95B
$13.7M 1.81%
490,000
+40,000
+9% +$1.2M
ACOG
16
Alpha Cognition
ACOG
$199M
$13.5M 1.78%
2,070,784
+1,955,642
+1,698% +$12.4M
ANNX icon
17
Annexon
ANNX
$942M
$13.1M 1.72%
2,600,000
– –
EWTX icon
18
Edgewise Therapeutics
EWTX
$4.64B
$12.4M 1.64%
500,000
– –
CDXS icon
19
Codexis
CDXS
$174M
$11.1M 1.46%
6,789,738
-6,005,262
-47% -$12.2M
PTGX icon
20
Protagonist Therapeutics
PTGX
$9.34B
$9.17M 1.21%
105,000
– –
GOSS icon
21
Gossamer Bio
GOSS
$83.2M
$8.43M 1.11%
2,720,000
-5,000
-0.2% -$14.3K
MBX
22
MBX Biosciences
MBX
$3.03B
$8.2M 1.08%
260,000
+7,000
+3% +$170K
RVMD icon
23
Revolution Medicines
RVMD
$44.6B
$7.96M 1.05%
100,000
– –
XOMA
24
DELISTED
Xoma
XOMA
$7.78M 1.03%
292,590
+37,503
+15% +$1.21M
DERM icon
25
Journey Medical
DERM
$211M
$7.52M 0.99%
975,000
+3,936
+0.4% +$30.9K
1
2 3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q4 2025 Portfolio in Review

As of Q4 2025, Opaleye Management held 63 positions worth $758M, up 7.1% from $707M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Opaleye Management deployed $36.9M of net new capital in Q4 2025, opening 21 new positions and adding to 16 existing holdings. Its largest new stake was Crescent Biopharma: 1,178,300 shares worth $14M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

On the sell side, the largest reduction was Rhythm Pharmaceuticals, an estimated $14M trimmed.

  • Opaleye Management's largest Q4 2025 buy was Crescent Biopharma: 1,178,300 shares worth $14M.
  • Opaleye Management added most to Rezolute in Q4 2025, an estimated $42.2M increase.
  • Opaleye Management's biggest Q4 2025 reduction was Rhythm Pharmaceuticals, cutting an estimated $14M.
  • Opaleye Management fully exited Immunome in Q4 2025, selling an estimated $37.3M.
  • Opaleye Management's ten largest holdings make up 65% of its $758M portfolio in Q4 2025.
  • Opaleye Management opened 21 new positions and closed 9 in Q4 2025.
  • Opaleye Management's portfolio value rose 7.1% quarter-over-quarter to $758M.

Based on Opaleye Management's 13F filing for Q4 2025, filed 17 Feb 2026.